Related Experiment Video

Updated: Jul 4, 2026

Murine Aortic Crush Injury: An Efficient In Vivo Model of Smooth Muscle Cell Proliferation and Endothelial Function
06:14

Murine Aortic Crush Injury: An Efficient In Vivo Model of Smooth Muscle Cell Proliferation and Endothelial Function

Published on: June 11, 2017

Simvastatin reduces endothelial activation and damage but is partially ineffective in inducing endothelial repair in

Nicoletta Del Papa1, Michela Cortiana, Claudio Vitali

  • 1Department of Rheumatology, G. Pini Hospital, Milano, Italy. delpapa@gpini.it

The Journal of Rheumatology
|June 6, 2008
PubMed

Insights

Simvastatin improved endothelial activation markers in systemic sclerosis (SSc) patients, but did not increase endothelial progenitor cells (EPCs), suggesting statins may treat vascular disease in SSc by modulating endothelial activation.

Area of Science:

  • Rheumatology
  • Cardiology
  • Vascular Biology

Background:

  • Systemic sclerosis (SSc) is associated with endothelial dysfunction and peripheral vascular disease.
  • Statins are known for their lipid-lowering effects and potential pleiotropic benefits, including anti-inflammatory and endothelial-protective properties.

Purpose of the Study:

  • To evaluate the efficacy of simvastatin in improving endothelial function in SSc patients.
  • To assess the impact of simvastatin on vasculogenesis, measured by endothelial progenitor cells (EPCs), and markers of vascular injury.

Main Methods:

  • A randomized controlled trial involving 20 SSc patients and 20 hypercholesterolemic controls treated with simvastatin 20 mg/day for 12 weeks.
  • Measurement of circulating endothelial progenitor cells (EPCs) and mature circulating endothelial cells (CECs) using flow cytometry.
  • Assessment of soluble adhesion molecules (E-selectin, ICAM-1, VCAM-1) and cytokines (IL-6, endothelin-1) via ELISA.

Main Results:

  • Simvastatin significantly increased EPCs in hypercholesterolemic controls but not in SSc patients, particularly those with late-stage disease.
  • SSc patients exhibited higher baseline CEC levels, which decreased significantly after simvastatin treatment.
  • Treatment with simvastatin led to a significant reduction in levels of soluble E-selectin, ICAM-1, VCAM-1, IL-6, and endothelin-1 in treated patients.

Conclusions:

  • Simvastatin rapidly and significantly improved markers of endothelial activation in SSc patients, indicating a potential therapeutic role in SSc-related peripheral vascular disease.
  • The inability to increase EPC levels in SSc patients suggests a defect in endothelial stem cell recruitment, independent of statin therapy.
  • The therapeutic benefits of statins in SSc may primarily stem from their ability to modulate endothelial activation pathways rather than enhancing vasculogenesis.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...